Cartalax

What is Cartalax?

Cartalax is a synthetic tripeptide consisting of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. According to the Khavinson program, its amino acid sequence corresponds to a motif in the alpha-1 chain of type XI collagen, a structural protein important for cartilage integrity. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in cartilage tissue. Its natural-extract counterpart is Sigumir, a complex of peptides derived from animal cartilage and bone tissue. The indexed research on AED is broader than the cartilage branding suggests: the same group has published cartilage-relevant cell studies (aging chondrocytes and stem cells, 2023), but also a larger set of kidney studies in which AED is coded T-31, and skin-fibroblast studies. Much of the mechanism detail quoted for Cartalax online actually comes from those kidney and skin papers.

What Cartalax Is Investigated For

Cartalax is a synthetic tripeptide from Vladimir Khavinson's bioregulator program investigated for cartilage protection, joint health, osteoarthritis, osteochondrosis, and anti-senescence effects in connective tissue cells. The cartilage-relevant evidence is two 2023 cell-culture papers from Khavinson-network authors: in aging human chondrocytes, AED normalized senescence and inflammation markers (lower p16, p21, p53, TNF-α, and IL-1α; restored SIRT1) (Myakisheva et al., PMID 37356100), and in aging human mesenchymal stem cells it switched on cartilage-building genes (SOX9, aggrecan, type II collagen, COMP) at 200 ng/mL (PMID 37782646). Other findings often quoted for Cartalax come from different tissues. SIRT6 increases were measured in kidney cells and skin fibroblasts, MMP-9 and caspase-3 suppression in skin fibroblasts, and Ki-67 in kidney tissue cultures. The widely repeated '18–38% increase in cartilage area index' could not be traced to any indexed paper. AED's largest published body of work is actually on the kidney, where it is coded T-31 and was tested in rat models of acute kidney injury. The central honest caveat is that the entire evidence base comes from a single research orbit: there are no PubMed-indexed human RCTs, no independent Western replication of the in vitro findings, and the Khavinson program's central claim of direct DNA interaction by a tripeptide remains contested in the broader scientific community. Russian clinical reports of benefit in spinal osteochondrosis and osteoarthrosis are not indexed in Western databases and do not meet modern trial-methodology standards. Cartalax is not FDA-approved, not on the 503A compounding list, and not part of mainstream Western orthopedic practice.

History & Discovery

Cartalax was developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, as part of an effort to map short synthesized peptides to specific tissue-maintenance functions of larger natural-extract preparations. The natural-extract counterpart is Sigumir, a peptide complex from animal cartilage and bone tissue that the Khavinson group had studied for several decades. The synthesized tripeptide Ala-Glu-Asp (AED) was identified on the basis that its sequence matches a motif found in the alpha-1 chain of type XI collagen — a structural protein critical to cartilage integrity — and the hypothesis was that delivering this minimal sequence exogenously would help reactivate cartilage-maintenance gene programs that decline with age. The published research on the AED sequence is spread across organs rather than concentrated on cartilage. Between 2014 and 2018, Khavinson-affiliated groups (Zamorskii, Shchudrova, Lin'kova, Chalisova and colleagues) published a series of kidney papers in which AED was coded T-31 and tested alongside the EDL tripeptide (T-35, the Ovagen sequence) in rat acute kidney injury and aging kidney cell cultures. Skin-fibroblast studies followed in 2016 and 2020. Cartilage-specific work arrived later: in 2023, Myakisheva, Lin'kova, Ryzhak and colleagues reported AED effects in aging human chondrocytes and in mesenchymal stem cells undergoing chondrogenic differentiation, and wrote a review framing AED ('Kartalax') as a candidate for peptide bioregulation of osteoarthritis. Independent replication of any of these findings has not occurred, and there are no PubMed-indexed human RCTs for Cartalax. The clinical evidence cited in Russian Khavinson-program publications, including reports of effectiveness in spinal osteochondrosis, osteoarthrosis, and osteoporosis, is not independently indexed and has not been reproduced under Western trial-methodology standards.

How It Works

Cartalax is a tiny three-amino-acid peptide proposed to enter cartilage cells and interact with their DNA, reactivating genes involved in maintaining healthy cartilage. As we age, cartilage cells produce less collagen and protective matrix — Cartalax is thought to help reverse that decline by boosting the cell's own repair programs.

Cartalax (Ala-Glu-Asp) is proposed to penetrate cell membranes due to its small molecular size (~333 Da) and interact directly with DNA regulatory regions in chondrocytes and fibroblasts. The indexed in vitro findings, grouped by the cells they were measured in: Cartilage-relevant cells. In aging human chondrocytes with a senescence-associated secretory phenotype, AED normalized the markers that define that phenotype — lower p16, p21, and p53, lower TNF-α and IL-1α, and restored SIRT1 (Myakisheva et al., 2023, PMID 37356100). In aging human mesenchymal stem cells, 200 ng/mL AED increased expression of the chondrogenic genes and proteins SOX9, aggrecan, type II collagen, and COMP, an effect the authors compared with a cartilage polypeptide complex at 2000 ng/mL (PMID 37782646). Kidney cells, where AED is coded T-31. In aging renal cell cultures, AED increased proliferation, lowered p16, p21, and p53, and raised SIRT6 (PMID 25946838). In kidney tissue cultures from young and old rats it stimulated proliferation (Ki-67) and reduced apoptosis (PMID 26033601), and T-31 was reported to activate cell renewal in aging renal epithelium (PMID 24958378). Skin fibroblasts. AED suppressed caspase-3-dependent apoptosis and MMP-9 in aging rat skin fibroblasts (PMID 27259496), and raised SIRT1, SIRT6, and collagen I in aging human skin fibroblasts (PMID 33231794). So several effects often described as 'Cartalax in chondrocytes' — SIRT6, MMP-9, caspase-3, Ki-67 — were in fact measured in kidney or skin cells. The '18–38% cartilage area index' figure circulating online could not be traced to an indexed paper, and no indexed study tests Wnt/beta-catenin signaling for AED.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cartalax:

• 01Independent replication outside the Khavinson research program — the 2023 chondrocyte and stem-cell findings, and the earlier kidney and skin findings, have not been reproduced by any outside laboratory.
• 02Animal osteoarthritis data — a 2023 review from the originating group says AED has shown efficacy in animal OA models, but no such study is indexed in PubMed; the only indexed in vivo AED work is in rat kidneys.
• 03Tissue specificity — AED is reported to act on chondrocytes, kidney cells, skin fibroblasts, and periodontal ligament stem cells (PMID 30791821), which is hard to reconcile with the bioregulator premise that each short peptide targets one organ.
• 04Source of the '18–38% cartilage area index' figure — widely repeated in Cartalax marketing, but not traceable to any indexed paper.
• 05Blinded randomized controlled trials in humans for osteoarthritis, osteochondrosis, or any joint-health endpoint.
• 06Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tripeptide), distribution to cartilage tissue, and clearance have not been characterized.
• 07Mechanism specificity — direct DNA interaction by a tripeptide and the resulting cartilage-specific gene reactivation claim has not been independently validated.
• 08Long-term safety, particularly any effect on cartilage remodeling that could become problematic with chronic use or in subclinical malignancy.
• 09Theoretical cancer-promotion concern — agents that stimulate cellular proliferation in connective tissue raise class concerns for tumor risk that the available data does not adequately address.

Forms & Administration

Cartalax is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable protocols use subcutaneous administration. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Claims for cartilage protection, joint health, and connective-tissue restoration exceed what the evidence base — dominated by in vitro work from a single program — can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical supply outside Russian channels is not authorized for human use.

Timeline of Effects

Common Questions

Who Cartalax Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for Cartalax are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include concurrent use with chemotherapy or anti-proliferative agents, where Cartalax's proposed proliferation-stimulating effect on chondrocytes could be mechanistically opposed. Combination with other joint-active medications (NSAIDs, intra-articular corticosteroids, hyaluronate injections, glucosamine/chondroitin supplements) has not been formally studied for interaction. Patients on any regular medication should disclose Cartalax use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions